Day One Biopharmaceuticals (NASDAQ:DAWN) CFO Charles York II Sells 6,065 Shares of Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles York II sold 6,065 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total transaction of $70,354.00. Following the completion of the transaction, the chief financial officer directly owned 312,025 shares of the company’s stock, valued at approximately $3,619,490. This trade represents a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Day One Biopharmaceuticals Stock Down 2.7%

Shares of DAWN opened at $11.56 on Thursday. The business’s 50-day moving average price is $10.34 and its 200-day moving average price is $8.57. Day One Biopharmaceuticals, Inc. has a twelve month low of $5.64 and a twelve month high of $13.20. The stock has a market cap of $1.19 billion, a PE ratio of -7.61 and a beta of -1.26.

Key Stories Impacting Day One Biopharmaceuticals

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Neutral Sentiment: Short-interest data appears to contain reporting errors and shows effectively zero short interest as of Feb. 17, producing no clear bearish or bullish signal to the market; treat this figure with caution.
• Negative Sentiment: Multiple insider sales by senior executives on Feb. 17 — CEO Jeremy Bender sold 15,459 shares at $11.60 (disclosed in an SEC Form 4), CFO Charles N. York II sold 6,065 shares at $11.60, and other insiders (Adam Dubow, Lauren Merendino, Michael Vasconcelles) also sold stock at roughly $11.60 per share. These aggregated insider reductions (some single-digit to double-digit percentage drops in individual holdings) can be perceived negatively by investors as reduced insider exposure. CEO Form 4 CFO Form 4 Insider Form 4
• Negative Sentiment: Zacks preview flags that Day One may not have the setup for an earnings beat in its upcoming report, implying analysts expect a likely negative earnings surprise — news that can weigh on sentiment ahead of the release. Zacks preview

Analyst Ratings Changes

Several analysts have issued reports on DAWN shares. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of Day One Biopharmaceuticals in a research report on Monday, November 24th. Piper Sandler upped their target price on shares of Day One Biopharmaceuticals from $25.00 to $26.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Needham & Company LLC reissued a “buy” rating and set a $16.00 price target on shares of Day One Biopharmaceuticals in a research report on Monday, November 24th. JPMorgan Chase & Co. increased their price target on shares of Day One Biopharmaceuticals from $26.00 to $27.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $25.71.

Institutional Trading of Day One Biopharmaceuticals

A number of large investors have recently made changes to their positions in DAWN. Federated Hermes Inc. bought a new position in Day One Biopharmaceuticals in the 3rd quarter worth about $39,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Day One Biopharmaceuticals by 26.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,989 shares of the company’s stock worth $46,000 after purchasing an additional 1,029 shares during the period. Ameritas Investment Partners Inc. raised its position in Day One Biopharmaceuticals by 44.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,349 shares of the company’s stock valued at $48,000 after purchasing an additional 2,264 shares in the last quarter. Quarry LP bought a new position in shares of Day One Biopharmaceuticals during the 3rd quarter worth $49,000. Finally, Entropy Technologies LP purchased a new position in shares of Day One Biopharmaceuticals during the second quarter valued at $67,000. 87.95% of the stock is owned by hedge funds and other institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.